AG
BIIB icon

Ascent Group’s Biogen BIIB Stock Holding History

Ascent Group’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Buy
6,852
+16
+0.2% +$3.06K 0.04% 315
2026
Q1 		$1.25M Buy
6,836
+802
+13% +$148K 0.04% 326
2025
Q4 		$1.06M Buy
6,034
+2,086
+53% +$341K 0.04% 358
2025
Q3 		$553K Buy
3,948
+1,234
+45% +$167K 0.02% 476
2025
Q2 		$341K Buy
+2,714
New +$338K 0.01% 551

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ascent Group's BIIB Position: Q2 2026 in Review

Ascent Group increased its Biogen (BIIB) stake by 0.23% in Q2 2026, buying an estimated $3.06K and bringing the position to 6,852 shares worth $1.48M. The position accounts for 0.04% of the portfolio, ranked #315.

Ascent Group first reported a position in BIIB in Q2 2025 and has held it in 5 quarters since. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Ascent Group held 6,852 shares of Biogen worth $1.48M as of Q2 2026.
  • Ascent Group bought 16 Biogen shares in Q2 2026, an estimated $3.06K.
  • Biogen made up 0.04% of Ascent Group's portfolio in Q2 2026, its #315 holding.
  • Ascent Group first reported a position in Biogen in Q2 2025 and has held it in 5 quarters since.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Ascent Group's 13F filing for Q2 2026, filed 3 Aug 2026.